Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment

TipRanksNov 22 06:25 ET · Ratings

Akero a New Buy at Citi on Liver Disease Asset

Seeking AlphaNov 18 12:33 ET

Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup

Dow JonesNov 18 07:51 ET · Ratings

Promising Potential of Akero Therapeutics' Efruxifermin Highlighted by Positive Phase 2b HARMONY Study Results

TipRanksNov 18 06:35 ET

Akero Therapeutics (AKRO) Receives a Buy From Phillip Securities

TipRanksNov 18 05:18 ET · Ratings

Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics

TipRanksNov 17 09:35 ET · Ratings